

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
24 April 2025 (24.04.2025)



(10) International Publication Number
WO 2025/083205 A1

(51) International Patent Classification:

A61K 47/68 (2017.01) *A61K 45/06* (2006.01)
A61K 31/5377 (2006.01) *A61P 35/00* (2006.01)
A61K 31/635 (2006.01) *A61K 31/52* (2006.01)

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2024/079491

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(22) International Filing Date:

18 October 2024 (18.10.2024)

Published:

— with international search report (Art. 21(3))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23204446.1 18 October 2023 (18.10.2023) EP
24195593.9 21 August 2024 (21.08.2024) EP

(71) Applicant: **DEBIOPHARM INTERNATIONAL S.A.**
[CH/CH]; Forum "après-demain", Chemin Messidor 5-7,
1006 Lausanne (CH).

(72) Inventors: **BERTONI, Francesco**; Fondazione per l'Istituto Oncologico di, Ricerca, Institute of Oncology Research, Via Francesco Chiesa 5, 6500 Bellinzona (CH). **ARRIBAS, Alberto**; Fondazione per l'Istituto Oncologico di, Ricerca, Institute of Oncology Research, Via Francesco Chiesa 5, 6500 Bellinzona (CH). **NAPOLI, Sara**; Fondazione per l'Istituto Oncologico di, Ricerca, Institute of Oncology Research, Via Francesco Chiesa 5, 6500 Bellinzona (CH).

(74) Agent: **HOFFMANN EITLE PATENT- UND RECHTSANWÄLTE PARTMBB, ASSOCIATION NO. 151**; Arabellastraße 30, 81925 Munich (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: DRUG COMBINATION COMPRISING ANTI-CD37 ANTIBODY MAYTANSINE CONJUGATE AND BCL2 INHIBITOR OR PI3K INHIBITOR

(57) Abstract: The present invention relates to drug combinations for the treatment of disease. In particular, the present invention relates to combinations comprising ligand-drug- conjugates targeting CD37 together with a co-agent selected from BCL2 inhibitors and inhibitors of the PI3K pathway and uses thereof in the treatment of cancer and especially DLBCL.

WO 2025/083205 A1